NEW! LeukoStrat® CDx FLT3 Mutation Assay Kit READ MORE Invivoscribe PRODUCTS & SERVICES SCIENCE RESOURCES COMPANY LOGIN CATALOG ORDER SUPPORT CONTACT SEARCH Test results matter Internationally harmonized diagnostics State-of-the-art facilities From our brand new global headquarters in San Diego, to our new facilities in Asia. Invivoscribe is paving the way for ground-breaking medicine. Contact Us Go Fast Forward with Invivoscribe NGS. Minimal residual disease testing with a full suite of LymphoTrack assays. Find out more. Go Connections that make impact. Globally harmonized labs, and globally unified collaborations. See us at our next event. Go Cutting-edge bioinformatics software. Complete solutions and comprehensive bioinformatics to fit any need. Find out more. Go INNOVATORS OF DIAGNOSTIC TESTS THAT IMPACT TREATMENT Invivoscribe is an industry pioneer with over 20 years of experience developing and manufacturing diagnostic products and reagents for leukemias and lymphomas. All of our diagnostic tests generate meaningful results allowing healthcare providers to confirm or modify treatment for each patient. LEARN MORE ABOUT INVIVOSCRIBE Go LATEST NEWS  Apr 28, 2017: Invivoscribe announces the premarket approval of LeukoStrat® CDx FLT3 Mutation Assay service. The FLT3 mutation testing with LeukoStrat® CDx FLT3 Mutation Assay is exclusively performed by The Laboratory for Personalized Molecular Medicine, a subsidiary of Invivoscribe Technologies, Inc. PRESS RELEASE: FDA approves new combination treatment for acute myeloid leukemia The U.S. Food and Drug Administration approves the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML. READ  GENERATING CLINICALLY ACTIONABLE RESULTS THAT OPTIMIZE PATIENT TREATMENTS Our assays, services, and bioinformatics are used to identify subtypes of disease to inform and guide the patient’s physician from diagnosis through the entire course of therapy. We use the latest validated technologies to support diagnosis and monitoring of hematologic diseases, including clonality and biomarker testing, companion diagnostics, and testing for minimal residual disease (MRD). Bioinformatics Clinical Services Products Companion Diagnostics Our portfolio includes an unparalleled range of tests and technologies. We follow quality system regulation (QSR) design control (ISO 13485) and all reagent manufacturing is conducted with our own cGMP facility. Regulatory expertise is provided through each milestone, ensuring safety, efficacy, and quality to produce best in class companion diagnostics. LEARN MORE Go CONTINUOUSLY INVESTING IN THE ADVANCEMENT OF PERSONALIZED MOLECULAR MEDICINE® We work with a full range of collaborators: key opinion leaders; leading healthcare institutions; top-tier pharmaceutical companies; and, most importantly, patients seeking to better understand their individual disease when they include their physicians in the dialogue. Quality Internationally harmonized diagnostics. We follow full QSR design control for assay and software development. Products are manufactured under cGMP and ISO 13485. Our global network of Laboratories for Personalized Molecular Medicine are CLIA/CAP accredited, New York State licensed in the US, and ISO 15189/DAkkS certified in Germany. Our new clinical lab in Japan opened Summer 2016. LEARN MORE ABOUT CERTIFICATIONS Go Partnership We support partnerships worldwide to develop, validate, and commercialize molecular assays and reagents. Our global distribution network operates in more than 700 laboratories in over 100 countries. PHARMA LABS PROVIDERS DISTRIBUTORS Expertise With over 20 years of experience we are the foremost experts in providing molecular products and services for leukemia and lymphoma testing. We offer dedicated support in design and development, manufacturing, software and bioinformatics, technical support, quality assurance, and global regulatory affairs. LEARN MORE ABOUT LEADERSHIP Go IMPROVING THE PATIENT EXPERIENCE We are focused on advancing personalized molecular medicine, acknowledging each patient’s journey is unique, and influenced by driver mutations and their own genetic factors. Our tests can make a difference in the outcome for each patient by identifying how an individual patient will respond to a given therapy. In partnership with a patient’s physician, we can tailor specific treatments to match an individual’s driver mutations and disease. Personalized molecular medicine is a proactive approach that provides critical information to guide treatment decisions. SEE HOW WE SERVE PATIENTS Go © 2016 Invivoscribe Sitemap Terms and Conditions Web Privacy Policy Corporate Privacy Policy Licensure and Certifications Distributors Designed by Audacity Europe North America Asia